About Careers MedBlog Contact us

Generic Version of Copaxone, the Most-Used MS Drug, Receives FDA Approval

by Vishnuprasad on April 20, 2015 at 5:29 PM
Font : A-A+

Generic Version of Copaxone, the Most-Used MS Drug, Receives FDA Approval

The Food and Drug Administration (FDA) has approved the lower-cost version of Copaxone, the most-used drug for multiple sclerosis.

Teva Pharmaceutical Industries Ltd manufactures Copaxone. The generic drug, Glatopa, was developed collaboratively by Sandoz, a unit of Swiss drugmaker Novartis AG, and Momenta Pharmaceuticals Inc, for treating patients with relapsing forms of the chronic neurodegenerative disease.


However, the companies are still engaged with the patent litigation. Sreejit Mohan, spokesman of Sandoz, said the company would not comment on commercial launch plans.

Sources with Momenta said the 20 mg generic version of the blockbuster drug could be labeled 'substitutable', meaning prescriptions for Copaxone could be automatically switched to the generic.

Teva's U.S. sales of Copaxone totaled $3.1 billion in fiscal 2014. The company has been working to switch patients to a 40 mg formulation of the drug that still has patent protection.

Source: Medindia


Latest Drug News

 Parkinson's Unmet Needs Creates Path for New Entrants into the Market
Addressing the unmet needs of Parkinson's Disease by providing disease-modifying therapies could bring about a major shift in the way that patients are treated.
How Microrobots Could Help Treat Bladder Diseases?
Microrobots could swirl through a person's blood stream, search for targeted areas to treat for various ailments.
How Can Multivitamin Supplements Slow Cognitive Aging?
Supplementation with multivitamins is an inexpensive way for older adults to slow down memory loss.
 Ivosidenib Approved for Acute Myeloid Leukemia & Advanced Cholangiocarcinoma
Some people with an aggressive blood cancer called acute myeloid leukemia (AML) may soon have a new drug option called Ivosidenib that blocks the activity of IDH1 gene.
Sacubitril/valsartan Unleashes Hope for Heart Failure Patients
In case of cardiac failure where the ejection fraction is greater than 40%, sacubitril/valsartan can prove to be quite beneficial
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Generic Version of Copaxone, the Most-Used MS Drug, Receives FDA Approval Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests